Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jul;8(7-8):E540-4.
doi: 10.5489/cuaj.1411.

Complications of intravesical bacillus calmette-guérin

Liam C Macleod  1 , Tin C Ngo  2 , Mark L Gonzalgo  2
Affiliations

Complications of intravesical bacillus calmette-guérin

Liam C Macleod et al. Can Urol Assoc J. 2014 Jul.

Abstract

Intravesical Bacillus Calmette-Guérin (BCG) is an important treatment for the management of non-muscle invasive bladder cancer because of its proven efficacy and favourable safety profile. The most common complications associated with BCG treatment are relatively minor. They include urinary frequency, cystitis, fever, and hematuria. Although serious complications are rare, patients can develop severe, life-threatening sepsis with disseminated mycobacterial infection. We report a rare case of periurethral diverticulum formation after intravesical BCG and review the literature on the potential complications of this treatment modality.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Computed tomography (CT) scan of a patient with a painful, fluctuant perineal mass after intravesical BCG instillation.
Fig. 2.
Fig. 2.
Retrograde urography demonstrating the presence of a pendulous periurethral diverticulum in the area of the perineal mass.
Fig. 3.
Fig. 3.
Retrograde urography demonstrating resolution of the periurethral diverticulum following aspiration.
See this image and copyright information in PMC

References

    1. Morales A, Eidinger D, Bruce AW. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116:180–3. - PubMed
    1. Lamm DL. Comparison of BCG with other intravesical agents. Urology. 1991;37:30–2. doi: 10.1016/0090-4295(91)80136-U. - DOI - PubMed
    1. Jakse G. BCG for carcinoma in situ. Eur Urol. 1992;21(Suppl 2):30–4. - PubMed
    1. Sylvester RJ, Van der Meijden APM, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168:1964–70. doi: 10.1016/S0022-5347(05)64273-5. - DOI - PubMed
    1. Kamat AM, Lamm DL. Immunotherapy for bladder cancer. Curr Urol Rep. 2001;2:62–9. doi: 10.1007/s11934-001-0027-7. - DOI - PubMed

LinkOut - more resources